XML 28 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Gain (Loss)
Beginning balance (in shares) at Dec. 31, 2022   4,830,464      
Beginning balance at Dec. 31, 2022 $ 46,552 $ 48 $ 1,195,687 $ (1,148,997) $ (186)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 6,000   6,000    
Issuance of common stock in connection with 2021 Sales Agreement, net of fees (in shares)   920,488      
Issuance of common stock in connection with Sales Agreement, net of fees 13,814 $ 9 13,805    
Issuance of common stock under employee benefit plans, including restricted stock awards (in shares)   149,633      
Issuance of common stock under employee benefit plans 302 $ 2 300    
Cancellation of restricted stock awards (in shares)   (6,500)      
Cancellation of restricted stock awards 0        
Unrealized gain (loss) on marketable securities 415       415
Net loss $ (47,413)     (47,413)  
Ending balance (in shares) at Dec. 31, 2023 5,894,085 5,894,085      
Ending balance at Dec. 31, 2023 $ 19,670 $ 59 1,215,792 (1,196,410) 229
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 5,927   5,927    
Issuance of common stock in connection with October 2024 Financings, net of issuance costs (in shares)   2,398,414      
Issuance of common stock in connection with October 2024 Financings, net of issuance costs 5,972 $ 24 5,948    
Issuance of common stock in connection with 2021 Sales Agreement, net of fees (in shares)   188,316      
Issuance of common stock in connection with Sales Agreement, net of fees 1,112 $ 2 1,110    
Issuance of warrants in connection with October 2024 Financings, net of issuance costs 4,798   4,798    
Issuance of common stock under employee benefit plans, including restricted stock awards (in shares)   11,378      
Issuance of common stock under employee benefit plans 141   141    
Cancellation of restricted stock awards (in shares)   (4,375)      
Cancellation of restricted stock awards 0        
Unrealized gain (loss) on marketable securities (229)       (229)
Net loss $ (43,389)     (43,389)  
Ending balance (in shares) at Dec. 31, 2024 8,487,818 8,487,818      
Ending balance at Dec. 31, 2024 $ (5,998) $ 85 $ 1,233,716 $ (1,239,799) $ 0